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In Europe there is considerable variation in mortality on renal
replacement therapy (RRT). The causes of this variation are
still poorly understood. We hypothesized that differences in
mortality in the general population contribute to differences
in mortality on RRT. To evaluate this relationship, we studied
general population statistics obtained from Eurostat and the
individual data of 67 692 patients on RRT from 15 national
and regional renal registries. These 15 registries were divided
into two geographical regions: North and South Europe. Cox
regression was used to assess the relative risk of death (RR)
for each region with adjustment for age, gender, diabetes,
and additionally general population mortality. In patients on
RRT the age, gender and diabetes adjusted RR of death was
0.65 (95% CI (0.64–0.66)) for South compared to North, while
in the general population the age and gender standardized
RR of death was 0.91. After adjustment for general
population mortality in addition to age, gender, and
diabetes, the RR of death for patients on RRT in the South
changed from 0.65 to 0.74 (95% CI (0.72–0.75)), which
indicates that general population mortality accounted for
26% of the region-related mortality difference on RRT.
In conclusion, within Europe there exist considerable
international differences in the mortality of patients on RRT.
Twenty-six percent of the European north–south mortality
difference in RRT could be attributed to differences in general
population mortality. Our data support the hypothesis that
general population mortality is an important factor to take
into account when making RRT mortality comparisons.
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End-stage renal disease is a rapidly increasing health
problem. In the European Union, it has been estimated that
2–3% of the health care budget1–3 is spent on renal
replacement therapy (RRT) by hemodialysis, peritoneal
dialysis, and transplantation for patients who comprise only
0.1% of the general population.4 Although RRT prolongs
survival in patients with end-stage renal disease, the risk of
death on RRT remains very high compared to the general
population. However, in Europe there are considerable
differences in mortality of patients on RRT, suggesting a
north–south gradient.5,6
Several factors have been suggested to contribute to this
variation: differences in referral to nephrologists,7 access to
RRT,8 in patient demographics, cause of end-stage renal
disease and the presence of co-morbidities,5,9,10 and in RRT
practice patterns.11,12 Although previous international com-
parison studies have shown that several of these factors may
account for some of the variation in RRT mortality,5,11,12
large differences in RRT mortality comparisons between
countries remained.10
The impact of general population mortality on RRT
mortality in Europe has never been assessed before. We
hypothesized that differences in mortality in the general
population contribute to differences in the mortality of
patients on RRT. In this study, we aimed to investigate this
relationship using the data from 15 European registries,
which collaborate within the European Renal Association-
European Dialysis and Transplant Association Registry.
RESULTS
Patient characteristics
Table 1 shows the characteristics of patients who started RRT
during the period 1996–2000, according to country or region
of origin. In general, there was a tendency towards higher
RRT incidences in the southern regions (125.4 per million
population (PMP)) compared to the northern regions
(106.2 PMP) and this north–south difference was larger in
the incidence of patients aged 65 years or older. The across
country difference was about 62 PMP with Norway having
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the lowest (84.6 PMP) and the Spanish region Valencia
(146.2 PMP) the highest incidence. The mean age of patients
on RRT was generally higher in the southern (62.7 years) than
in the northern region (60.7 years).
The effect of general population mortality on RRT mortality
As indicated in the upper panel of Figure 1, a north–south
gradient was present in the mortality of patients on RRT
(y axis) and to a lesser extent in the mortality of the general
population (x axis). The crude annual death rate of patients
on RRT ranged from 200 per 1000 patient years (py) in the
North to 132 per 1000 py in the South. The mortality on RRT
was highest in Sweden (239 per 1000 py) and lowest in
Basque country (118 per 1000 py). In the general population,
the mortality rate (deaths per 100 000 population per year)
was 1022 per 100 000 in the northern region and 969 per
100 000 in the southern region (RR¼ 0.95). Scotland had the
highest (1162 per 100 000) and Basque country (875 per
100 000) the lowest general population mortality rate. Our
data showed a significant association between mortality in
the general population and mortality in patients on RRT
(r¼ 0.68; P¼ 0.007).
The lower panel of Figure 1 shows the age, gender, and
diabetes adjusted mortality for the RRT population, and the
age and gender standardized mortality rate for the general
population. The standardized general population mortality
rate was 1017 per 100 000 population in the northern region
and 921 per 100 000 in the southern region (RR¼ 0.91). After
these adjustments, the association between general popula-
tion and RRT mortality slightly dropped to r¼ 0.57
(P¼ 0.03), which implies that about 32% (r2) of the
north–south variability in RRT mortality may be put down
to the observed variation in general population mortality.
Figure 2 shows the relative risks (RR) of death for patients
on RRT, unadjusted (upper panel) and adjusted (lower
panel) for age, gender, and diabetes, and additionally for
general population mortality. By using the North as the
reference group, the crude RR of death was lower in the
southern region (RR¼ 0.76, 95% CI (0.74–0.78)). The age,
gender, and diabetes adjusted RR (lower panel, white
symbols) depicts an even more marked mortality difference
between the two regions (RR¼ 0.65, 95% CI (0.64–0.66)),
which was mainly due to the relatively higher mean age of
incident RRT patients in the South of Europe. The
assessment of the age, gender, and diabetes adjusted RRs of
death for patients who survived the first 90 days and the
analysis over different age bands for patients with and
patients without diabetes provided similar results. Separate
analyses for patients on dialysis and transplanted patients
revealed a comparable north–south mortality gradient.
In order to quantify the effect of general population
characteristics on RRT mortality, we further adjusted for
general population mortality (lower panel, black symbols).
This resulted in a reduction of the mortality difference
between the regions as indicated by the increase of the RR of
the southern region from 0.65 (95% CI (0.64–0.66)) to 0.74
(95% CI (0.72–0.75)). In other words, patients in the South
had 35% lower mortality in the first model and 26% in the
second model. Analysis by cohort (1996–1998 and
1999–2000) showed comparable results. The 9% difference
indicated that 26% (9 divided by 35) of the north–south
difference in mortality on RRT could be attributed to
Table 1 | Demographic characteristics of incident patients on RRT by country (n=67 692; 1996–2000)
Incidence of RRT PMP by age group
Number of
new RRT
patients
Mean age
(years) % Male All ages 45–64 65–74 75+
Incidence of RRT
PMP due to
diabetesa
North 41 819 60.7 60.5 106.2 152.6 369.3 290.2 22.1
Austria 5033 60.7 59.3 125.6 194.7 450.1 300.6 38.1
Belgium 6991 64.2 57.2 137.0 179.5 458.0 499.5 29.4
Denmark 2993 58.7 62.5 112.9 170.2 394.2 237.7 24.6
Finland 2207 57.1 61.8 85.7 132.6 290.6 132.4 28.0
Norway 1876 60.0 66.6 84.6 125.1 304.2 218.7 10.2
Sweden 5485 63.1 63.1 123.9 154.8 397.6 383.4 28.4
The Netherlands 7378 58.6 59.7 93.9 141.7 354.8 244.1 14.1
UK England/
Walesb
7241 60.5 61.6 90.6 132.6 303.5 229.9 15.4
UK Scotland 2615 59.2 58.2 102.1 149.9 348.8 244.3 18.8
South 25 873 62.7 61.2 125.4 167.0 392.1 364.1 21.1
Greece 6530 61.7 61.5 124.1 173.4 412.1 318.4 27.1
Italy (7 regions)c 11 053 63.7 61.0 119.4 145.4 345.7 368.0 16.5
Spain, Basque
country
1058 58.7 65.3 102.4 162.9 325.7 178.6 15.0
Spain, Catalonia 4333 63.0 61.6 140.3 188.8 464.2 445.1 27.1
Spain, Valencia 2899 61.4 59.5 146.2 231.3 499.9 418.7 20.4
aPrimary renal disease is diabetic nephropathy.
bPeriod coverage for the UK E/W is 1997–2000 with increasing coverage (18% in 1997, 50% in 2000).
cData for Italy describe the regions Basilicata, Calabria, Emilia-Romagna, Marche, Piemonte, Sardegna, and Veneto together covering 33% of Italy.
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differences in general population mortality. Also analysis by
country showed similar results although the RRs of Norway
and Sweden increased after adjustment for general popula-
tion mortality.
Further analysis showed that the mortality hazard for
Norway was not proportional over time due to its ex-
ceptionally high (pre-emptive) transplant rate. Therefore, we
also assessed the RRs of death for patients from Norway for
two distinct periods during follow-up time. This showed that
during the first two years after the start of RRT the age,
gender, diabetes, and general population mortality adjusted
RR of death for Norway was 1.24 (95% CI (0.96–1.61)) while
the RR was 0.67 (95% CI (0.59–0.75)) in the years thereafter
indicating an increasing survival advantage for Norwegian
patients over time.
Trends in RRT mortality
As our results indicated that general population mortality is a
factor to be taken into account when making RRT survival
comparisons, we also assessed the time trend in mortality
with adjustment for age, gender, and diabetes, and addition-
ally for general population mortality. We compared the
mortality of patients who started RRT in the period
1999–2000 to those who started in the period 1996–1998.
A decrease of RRT mortality took place in the North
(RR¼ 0.95, 95% CI (0.91–1.00), Po0.05) but the data
showed an increase in the RR of death in the South
(RR¼ 1.06, 95% CI (1.02–1.10)).
DISCUSSION
This is the first study to investigate the mortality differences
of patients on RRT across Europe taking into account
the potential impact of differences in general popula-
tion mortality. Our findings showed that patients on RRT
in the South of Europe had a 35% lower mortality and the
general population had a 9% lower mortality compared to
the North of Europe. Twenty-six percent of the European
north–south mortality difference in RRT could be attributed
to differences in general population mortality. Our
results therefore support the hypothesis that differences
in RRT mortality within Europe are partly explained
by (factors underlying) the differences in general popula-
tion mortality.
International differences in mortality of patients on RRT
have been subject of study for more than a decade. A study by
Held et al.9 was the first to report striking differences between
the US, Europe, and Japan. That publication was the starting
point of several initiatives aiming at the identification of
the underlying factors,13–17 among which was the Dialysis
Outcomes and Practice Patterns Study (DOPPS) in hemo-
dialysis patients. In all these studies, large international mor-
tality differences remained after correction for age, gender,
diabetes,9 race, and co-morbid diseases.10,15 In our study,
adjustment for age widened rather than narrowed the
north–south mortality gap in patients on RRT because those
in South European countries lived longer despite the fact that
they were older than their North European counterparts. Our
data suggest that in international RRT mortality comparisons
the factor of general population mortality, representing the
intrinsic mortality risk resulting from being part of a specific
population, seems at least as important as the factors age,
gender, and diabetes.
Factors underlying general population mortality
General population mortality may reflect both genetic and
environmental factors. Whereas in Europe with a mainly
white population such factors accounted for up to a quarter
of the mortality in patients on RRT, a study by the United
States Renal Data system (USRDS)18 comparing the mortal-
ity on RRT between Asian and Caucasian Americans showed
that a difference in race may account for up to 50% of an
RRT mortality difference. Although the difference in general
population mortality in that study was much higher than the
difference we found across Europe, one could speculate that
also the north–south gradient in general population mortality
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Figure 1 | Annual mortality rates in the general population
(x axis) and in patients on RRT (y axis) by country for the
period 1996–2000. Upper panel: crude all cause mortality. Lower
panel: adjusted all cause mortality.
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within Europe originates at least in part from genetic
differences between the populations described. Such
broad north–south gradients, spanning from the Levant to
northern and western parts of Europe, were demonstrated
for markers representing different allele frequencies at 120
protein loci.19 In addition to differences in mortality due
to genetic make-up in the source population, it may also be
that particular genetic profiles may induce additional
mortality risk once these persons develop end-stage renal
disease and are treated with RRT. The potential role of those
profiles and their specific mechanisms deserve further
investigation.
Environmental factors underlying general population
mortality will include lifestyle factors such as dietary
habits, smoking, the quality of and access to health care,
and socio-economic factors. Dietary patterns are associated
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Figure 2 | Country and region specific RR of death (plotted on a natural logarithmic scale) for incident patients on RRT (started RRT
during the period 1996–2000 with follow-up until December 31st 2003). Upper panel: crude RRs. Lower panel: adjusted RRs.
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with mortality from all causes and are known to vary across
countries in Europe. Data from the World Health Organiza-
tion (WHO) showed that southern European populations
have a higher intake of unsaturated lipids (olive oil),
vegetables, fruits and cereals, and wine.20,21 A large study
among elderly people in nine European countries summari-
zed the qualitative aspects of the Mediterranean diet in a
single score and they showed that adherence to a modified
Mediterranean diet was clearly associated with a longer life
expectancy.22 Moreover, the mean scores for the nine
European countries presented in that study showed a clear
north–south gradient. Wide access to and high quality of
health care may, however, compensate for less favorable other
lifestyle factors. Such may be the case in Sweden and Norway
that are known for their high living standards and free health
care and at the same time have a relatively low general
population mortality. The gross domestic product (GDP)
and the total health expenditure as a percentage of the GDP
have been used as crude socio-economic indicators and
indicators of access to healthcare. WHO data on this topic
did however not show a pattern completely consistent with
differences in general population mortality.21 General
population mortality therefore seems to emerge from a
complex interaction of factors.
Selection bias
If general population mortality accounts for a quarter of the
variation in RRT mortality, what other factors may then
contribute to the remaining differences? A factor that could
theoretically contribute to RRT mortality differences is
selection bias. In such a line of argument, one would expect
that in countries selecting the ‘healthiest’ patients a low
acceptance of patients to RRT would go hand in hand with a
high patient survival. In Europe there is, however, little
evidence that this is the case, as this study showed that the
regions with the highest, and not the lowest, incidence of
RRT (southern Europe) had the highest survival on RRT.
Also differences in the inclusion of RRT patients in registries,
especially of those dying soon after the start of RRT, could
result in differences in survival. In that case one would expect
that countries with a low registration of patients dying early
would for this reason have a higher RRT survival. However,
all registries have procedures to check the completeness of
patient inclusion. Secondly, in our study, we found that the
country specific RRs of death for patients on RRT in- and
excluding the first 90 days on RRT were very similar. These
findings indicate that selective registration of patients is not
an important issue either.
It has been suggested that timely referral and earlier
initiation of dialysis are related to lower mortality and
morbidity especially during the first months of RRT. A
report on referral patterns in 14 European dialysis centres
based on data from the early 1990s showed that there
was large variability in early versus late referral.7 The reported
referral patterns did not show a north–south mortality
gradient.
Practice patterns
Several practice patterns have been found to be associated
with mortality on RRT. In the US hemodialysis practice
patterns have been studied by McClellan et al.23,24 Currently,
international hemodialysis practice patterns are under
investigation in the DOPPS. In the DOPPS a wide range of
clinical performance indicators like dialysis dose, nutritional
parameters, type of dialyser membranes and anaemia
management,11,13 vascular access type,12 and adherence to
dialysis prescriptions25 are being monitored continuously for
a large number of centres across Europe. In this perspective,
it is important to note that the allocation of RRT treatment
modalities is known to be different across countries.4 As a
consequence of this and other factors, the characteristics and
prognosis of patients remaining on hemodialysis may differ
between those countries. For this reason, comparing
hemodialysis practice patterns alone, as has been done in
the DOPPS, may explain our findings only to a limited
extent. Nevertheless, DOPPS is the only international study
with an extensive clinical data collection and, therefore, by
reviewing the DOPPS reports, we have tried to relate country
specific hemodialysis practice patterns to mortality on RRT.
Despite the high mortality rates on RRT, patients in Sweden
had the highest hemoglobin levels. The international
differences in anemia management were however very small
and did not assist us to explain the differences in RRT
mortality we observed in this study. Of more assistance
was the finding that serum albumin, a marker for
inflammation and an important predictor of mortality, was
lowest in Swedish patients (Lopes A et al., DOPPS, manu-
script in preparation). In the perspective of our findings, we
also found it striking that the DOPPS found a clear
north–south difference among incident hemodialysis patients
in the use of native arterio-venous fistulas as vascular access.
Previous data showed that increased use of native AVF is
strongly associated with a reduction in mortality26 and recent
analyses showed that the use of those fistulas is indeed much
lower in the northern and western part of Europe in
comparison with South European countries (source: DOPPS
Symposium, Congress of the American Society of Nephro-
logy 2005, R Pisoni and FK Port, 16 December 2005, personal
communication). As these interesting results apply to
hemodialysis patients only, it is important to note that in
some but mainly North European countries, a large
percentage of the patients are treated with peritoneal dialysis
and DOPPS patients therefore represent selected populations.
As transplantation increases the life expectancy of RRT
patients, differences in access to transplantation may con-
tribute to differences in mortality. However, with the exception
of Norway, the percentage of patients receiving transplants was
too low and the international differences in transplant rates
were too small to explain differences in mortality between the
countries under study. In addition, transplant rates across
Europe lacked a north–south gradient.4
A meta-analysis by Devereaux et al.27 showed that in the
US the private for-profit status of dialysis centres is associated
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with an increased risk of death. As we did not have
information on for-profit status of European dialysis centres,
we were not able to investigate this potentially relevant factor.
Our data showed that after correction for age, gender,
diabetes, and general population mortality, the north–south
mortality difference tends to get smaller over time. This may
be related to the publication and dissemination of the
European Best Practice Guidelines28 and the Kidney Disease
Outcomes Quality Initiative guidelines,29 that may have reduced
previously existing differences in clinical practice. Further
identification of differences in RRT practice patterns across
Europe, within studies or as part of continuous quality impro-
vement initiatives through registries,30 may disclose additional
areas for improvement of RRT care and provide a scientific basis
for revision and further refinement of existing guidelines.
Strengths and limitations of the study
A strength of this study was the ability to assess the data of all
patients on RRT (including hemodialysis, peritoneal dialysis,
and transplanted patients) in a large number of European
countries and regions, thereby avoiding treatment allocation
bias. All contributors are known as well-established registries
and all but one had full coverage of the RRT population in
their area.
We did not have extensive co-morbidity data available for
adjustment in our Cox regression models. We were, however,
able to correct for age and diabetes mellitus as the cause of
renal failure, which both are strongly associated with other
co-morbid factors in this patient group. Moreover, a recent
European Renal Association-European Dialysis and Trans-
plant Association registry study showed that, with the
exception of Austria, the prevalence of co-morbid conditions
is very similar in patients starting RRT across the different
European countries.31
International differences in causes of death in patients on
RRT could have shed some light on potential causal factors.
Although we have information available on causes of death,
we decided to restrict ourselves to all cause mortality
comparisons as in many cases the causes of death of patients
on RRT are reported as unknown and this percentage varied
greatly across the countries considered in this study.
Conclusions
This study has shown that within Europe there exists a
considerable international difference in the mortality of
patients on RRT, especially between North and South Europe.
We could confirm our hypothesis that general population
mortality, reflecting the intrinsic mortality risk that each of
us runs just by being a member of a specific population,
accounts for an important part of the international variation
in mortality on RRT.
MATERIALS AND METHODS
Data collection
We used the data from 15 European registries including 67 692
patients who started RRT between 1996 and 2000. These 15
registries were divided into two geographical regions: the northern
region: Austria, Belgium (French and Dutch-speaking renal
registries), Denmark, Finland, Norway, Sweden, The Netherlands,
UK-Scotland and UK-England/Wales and the southern region:
Greece, Italy (seven regions: Basilicata, Calabria, Emilia Romagna,
Marche, Piedmont, Sardinia, and Veneto altogether representing
33% of the total Italian population) and in the regions Basque
country, Catalonia and Valencia in Spain. With exception of the UK
renal registry (England and Wales), all registries had full coverage
within their geographical area. The UK renal registry was established
in 1997, includes complete data for each participating centre in
England and Wales and increased its coverage to 50% in 2000 as
more renal centres were able to connect their renal IT systems to the
UK renal registry computer system.
In addition, we collected data on the demography and the yearly
death rates in the general population from Eurostat. These statistics
were available by age, gender and calendar year, for each country
and region mentioned for the period 1996–2000.32
Analyses
The incidence of RRT was defined as the number of new cases per
year divided by the mid-year general population. Patients on RRT
with a diagnosis of acute renal failure, patients not residing in the
area covered by a contributing registry and patients with a missing
start date were excluded.
Pearson correlations were calculated to assess the association
between mortality in the general population and mortality in
patients on RRT by country. Crude and adjusted annual mortality
rates for patients on RRT were calculated from the cumulative
survival probability at two years after the start of RRT. These
mortality rates as well as the crude and adjusted RRs of death were
determined using Cox regression. Adjustments have been performed
for age and gender, and for diabetes as the primary cause of
nephropathy. RRs were plotted on a natural logarithmic scale.
Proportional hazards assumptions were verified and non-propor-
tional hazards were assessed when needed. The first day on RRT was
taken as the starting point for the analysis of patient survival. The
death of the patient was the event studied; recovery of renal function
was defined as a censored observation. The follow-up time of
patients alive and on RRT ended on 31 December 2003 and was
censored at that date. Subgroup analyses were performed for
patients who survived the first 90 days of RRT, patients in different
age bands (0–19, 20–44, 45–64, 65–74 and 75þ ) and for patients
with and without diabetes as the primary cause of nephropathy.
General population mortality rates by country, gender, age in
5-year segments, and by calendar year were calculated as the number
of deaths per 100 000 population per year and standardized for age
and gender using the European Union 1995 reference population.32
To account for the impact of general population mortality on RRT
mortality differences, the natural log of the hazard of an individual
of the same sex and age in the general population was included in a
multiplicative Cox regression model.33 Statistical modelling and
estimation of the parameters was performed with SAS version 9.1
(SAS Institute, Cary, NC, USA).
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